Kobayashi Pharmaceutical
⚠️ High Risk
FEI: 3002324535 • Osaka, Osaka • JAPAN
FEI Number
3002324535
Location
Osaka, Osaka
Country
JAPANAddress
4 Chome 4-10, Dosho-Machi; Chuo, Osaka, Osaka, Japan
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).
NO ENGLISH
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 11/18/2025 | 54YCH99VITAMIN, MINERAL, PROTEINS AND UNCONVENTIONAL DIETARY SPECIALITIES FOR HUMANS AND ANIMALS, N.E.C. | 324NO ENGLISH | Division of West Coast Imports (DWCI) |
| 3/4/2025 | 60LAL99ANALGESIC, N.E.C. | Division of Southeast Imports (DSEI) | |
| 3/4/2025 | 60LAL99ANALGESIC, N.E.C. | Division of Southeast Imports (DSEI) | |
| 12/19/2023 | 65FBY06WATER, PURIFIED (EYEWASH) | Division of Southeast Imports (DSEI) | |
| 6/14/2023 | 64PBL01AMINOCAPROIC ACID (HEMOSTATIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/7/2022 | 86LPNACCESSORIES TO CONTACT LENSES - CLEANING AND WETTING AGENTS | Division of West Coast Imports (DWCI) | |
| 6/28/2005 | 89IQIORTHOSIS, LIMB BRACE | 118NOT LISTED | New Orleans District Office (NOL-DO) |
| 12/9/2004 | 65PCA02SILDENAFIL CITRATE (REGULATOR) | New Orleans District Office (NOL-DO) |
Frequently Asked Questions
What is Kobayashi Pharmaceutical's FDA import refusal history?
Kobayashi Pharmaceutical (FEI: 3002324535) has 8 FDA import refusal record(s) in our database, spanning from 12/9/2004 to 11/18/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Kobayashi Pharmaceutical's FEI number is 3002324535.
What types of violations has Kobayashi Pharmaceutical received?
Kobayashi Pharmaceutical has been cited for 5 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Kobayashi Pharmaceutical come from?
All FDA import refusal data for Kobayashi Pharmaceutical is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.